PLSE · Pulse Biosciences, Inc.
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-06 |
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
HAYWARD, Calif. --(BUSINESS WIRE)--Aug. 6, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, |
| 2026-07-30 |
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 30, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced plans to participate in the upcoming Canaccord Genuity 46 th Annual Growth |
| 2026-07-29 |
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 29, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the NANOPULSE-AF Study has surpassed its enrollment midpoint after |
| 2026-07-21 |
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 21, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter |
| 2026-07-15 |
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAYWARD, Calif. --(BUSINESS WIRE)--Jul. 15, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity |
| 2026-06-10 |
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
HAYWARD, Calif. --(BUSINESS WIRE)--Jun. 10, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about |
| 2026-05-27 |
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
HAYWARD, Calif. --(BUSINESS WIRE)--May 27, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming Goldman Sachs 47 th Annual Global Healthcare Conference |
| 2026-05-12 |
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
HAYWARD, Calif. --(BUSINESS WIRE)--May 12, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette, |
| 2026-05-08 |
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
HAYWARD, Calif. --(BUSINESS WIRE)--May 8, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to participate in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, |
| 2026-05-04 |
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results HAYWARD, Calif. --(BUSINESS WIRE)--May 4, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using |
| 2026-04-25 |
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 25, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology |
| 2026-04-20 |
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
nPulse™ Technology highlighted in late-breaking feasibility study and live case transmission HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 20, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today |
| 2026-04-17 |
Pulse Biosciences to Host Analyst Event on April 25, 2026
Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 17, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, |
| 2026-04-09 |
Pulse Biosciences Strengthens Executive Leadership Team
Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 9, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, |
| 2026-04-07 |
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif. --(BUSINESS WIRE)--Apr. 7, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, |